Objective: Total hip arthroplasty (THA) involves postoperative risks, such as thigh pain, periprosthetic fractures, and stress yielding. Short, anatomical, metaphyseal-fitting, cementless femoral stems were developed to reduce these postoperative risks. This study aimed to examine the "MiniMAX" prosthesis, which is a new generation, short, anatomical femoral stem made by Medacta.
Methods: Patients underwent a low-dose computed tomography scan. Femoral anteversion was measured. We assessed the position and anteversion of the femoral component and compared them with the unoperated side. We also assessed the patients' satisfaction and functional levels at 6 months postsurgery using the Harris Hip Score (HHS) and the Oxford Hip Score (OHS).
Results: Nineteen individuals were recruited in this study. We found no significant difference in femoral anteversion between the operated hip and the native hip. Using the HHS and OHS questionnaires, we found clinical improvement in the 6-month postoperative scores compared with the preoperative scores.
Discussion: The new-generation, short, anatomical femoral stem made by Medacta is successful in reproducing natural femoral anteversion, while also improving patients' functioning and lifestyle. Future large-scale, prospective comparison trials are required to further investigate this topic.
Keywords: MiniMAX prosthesis; Total hip arthroplasty; femoral anteversion; hip score; osteoarthritis; short femoral stem.